Seeking Global Awareness for Millions of Sufferers
Enroll in the Dupuytren Study Today!
and please participate in our fundraiser for the cure:
The International Dupuytren Data Bank (IDDB) is open for enrollment. Register today! Please watch Dr. Eaton's presentation at the International Conference. The first link below is to the study registration. The last link is a brochure that explains more about the study!
Dr. Charles Eaton presents on the IDDB at the International Conference in Groningen
The Dupuytren Research Group is conducting research to develop a blood test for Dupuytren disease. A blood test is the missing piece of the puzzle needed to develop and test medical treatments for Dupuytren disease and related conditions. Right now, the ruler, protractor and camera are the only nonsurgical tools to measure a person's Dupuytren/Ledderhose disease. These only show what has already happened, not what is happening right now. A blood test could show what is happening right now, including the biologic response to medical treatment or to changes in diet, physical activity, or other lifestyle changes - before any changes in lumps or angles. A blood test could be used to test medical treatments for Dupuytren disease more quickly and accurately than has ever been possible.
The first goal of the Dupuytren Research Group's International Dupuytren Data Bank (IDDB) is to develop a Dupuytren blood test. This research is organized in three stages. Stage one is a large online survey of people with Dupuytren/Ledderhose disease - severity, how it impacts their lives, and how other medical factors relate to their disease. Stage two is collecting blood samples from stage one participants and analyzing these samples for genetic, immune, inflammation, dietary, and others factors. Stage three is comparing blood test findings with the severity of Dupuytren disease. Stage one launched in 2015 and is growing daily. Stages two and three will be repeated in competitive cycles. Each cycle will select groups of people based on disease severity, collect their blood samples, and identify the best blood tests to repeat in the next cycle. Following cycles will do the same with more people and fewer tests until the best tests are confirmed. This strategy is designed to reduce overall costs. This strategy of repeated testing is also the fastest way to confirm the accuracy and reliability of a test available to all researchers to develop a cure for Dupuytren disease and related conditions. IDDB online enrollment is http://Dupstudy.com.
Dr. Charles Eaton
The Dupuytren Research Group